Drug intelligence / Profile preview

IN006

Development stage: Phase 2
Lead developer: Innorna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Parenteral, Intramuscular

Overview

**IN006** is an investigational bivalent lipid nanoparticle-formulated mRNA vaccine developed by Innorna for prevention of respiratory syncytial virus infection. It encodes stabilized prefusion fusion glycoprotein F antigens from both respiratory syncytial virus subgroup A and subgroup B, with the aim of inducing neutralizing humoral and cellular immune responses against both major RSV subgroups. IN006 is in Phase 2 clinical development in older adults, including evaluation of revaccination schedules. This record refers specifically to Innorna's non-hyphenated IN006 RSV vaccine, not Inhalon Biopharma's distinct inhaled antibody candidate IN-006.

Other names: Bivalent RSV mRNA vaccine

Targets

PRRs (Pattern recognition receptors sensing mRNA/LNP)Respiratory syncytial virus fusion glycoprotein (prefusion)

Beyond the preview

Go deeper on IN006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN006.

Explore the full profile